Literature DB >> 8432849

Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon.

R T Means1, S B Krantz.   

Abstract

We have previously reported that inhibition of human CFU-erythroid (E) colony formation by tumor necrosis factor (TNF) is an indirect effect mediated by a soluble factor released from a fraction of marrow accessory cells which are predominantly stromal elements (Means, R. T., Jr., E. N. Dessypris, and S. B. Krantz. 1990. J. Clin. Invest. 86:538-541). Further studies reported here identify a mediator of this effect. The inhibitory effect of recombinant TNF on marrow CFU-E is ablated by neutralizing antibodies to human beta IFN, but not by antibodies to gamma IFN or IL-1. Anti-beta IFN also neutralizes the inhibitory effect of conditioned medium prepared from marrow cells exposed to TNF. Human beta IFN inhibits colony formation by unpurified marrow CFU-E as well as highly purified CFU-E generated from peripheral blood progenitors, and limiting dilution analysis shows that this is a direct inhibitory effect. TNF has been implicated in the pathogenesis of the anemia of chronic diseases since blood TNF levels are elevated in many patients with this syndrome, and since exposure to TNF produces a similar anemia in either humans or mice. The present study demonstrates that beta IFN is a required mediator of this inhibitory effect on erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432849      PMCID: PMC287940          DOI: 10.1172/JCI116216

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  BALB/c-3T3 fibroblasts resistant to growth inhibition by beta interferon exhibit aberrant platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor signal transduction.

Authors:  L J Mundschau; D V Faller
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

2.  Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells.

Authors:  R T Means; E N Dessypris; S B Krantz
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  Improved plasma culture system for production of erythrocytic colonies in vitro: quantitative assay method for CFU-E.

Authors:  D L McLeod; M M Shreeve; A A Axelrad
Journal:  Blood       Date:  1974-10       Impact factor: 22.113

4.  Depletion of stromal cell elements in human marrow grafts separated by soybean agglutinin.

Authors:  W Ebell; H Castro-Malaspina; M A Moore; R J O'Reilly
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

Review 5.  Erythropoiesis in culture.

Authors:  A C Eaves; C J Eaves
Journal:  Clin Haematol       Date:  1984-06

6.  Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny.

Authors:  H Castro-Malaspina; R E Gay; G Resnick; N Kapoor; P Meyers; D Chiarieri; S McKenzie; H E Broxmeyer; M A Moore
Journal:  Blood       Date:  1980-08       Impact factor: 22.113

7.  Tumor necrosis factor acts synergistically with autocrine interferon-beta and increases interferon-beta mRNA levels in human fibroblasts.

Authors:  L F Reis; T Ho Lee; J Vilcek
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

8.  Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice.

Authors:  R A Johnson; T A Waddelow; J Caro; A Oliff; G D Roodman
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

Review 9.  The anemia of chronic disease.

Authors:  G R Lee
Journal:  Semin Hematol       Date:  1983-04       Impact factor: 3.851

10.  Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development.

Authors:  K Sawada; S B Krantz; E N Dessypris; S T Koury; S T Sawyer
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

View more
  27 in total

Review 1.  Anemia of inflammation.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Hematol Oncol Clin North Am       Date:  2014-05-28       Impact factor: 3.722

Review 2.  Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease.

Authors:  M Jongen-Lavrencic; H R Peeters; G Vreugdenhil; A J Swaak
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

3.  Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations.

Authors:  Gail Dallalio; Erin Law; Robert T Means
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

Review 4.  Anemia of thermal injury: combined acute blood loss anemia and anemia of critical illness.

Authors:  Joseph A Posluszny; Richard L Gamelli
Journal:  J Burn Care Res       Date:  2010 Mar-Apr       Impact factor: 1.845

5.  Inhibition of in vitro erythropoiesis by soluble mediators in Plasmodium chabaudi AS malaria: lack of a major role for interleukin 1, tumor necrosis factor alpha, and gamma interferon.

Authors:  G S Yap; M M Stevenson
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Activation of protein kinase C{eta} by type I interferons.

Authors:  Amanda J Redig; Antonella Sassano; Beata Majchrzak-Kita; Efstratios Katsoulidis; Hui Liu; Jessica K Altman; Eleanor N Fish; Amittha Wickrema; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

7.  Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response.

Authors:  Chanté L Richardson; Lorrie L Delehanty; Grant C Bullock; Claudia M Rival; Kenneth S Tung; Donald L Kimpel; Sara Gardenghi; Stefano Rivella; Adam N Goldfarb
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

8.  Loss of LKLF function results in embryonic lethality in mice.

Authors:  M A Wani; R T Means; J B Lingrel
Journal:  Transgenic Res       Date:  1998-07       Impact factor: 2.788

9.  Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis.

Authors:  Kyung Hwan Jeong; Tae Won Lee; Chun Gyoo Ihm; Sang Ho Lee; Ju Young Moon
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

10.  The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.

Authors:  Min Kyoung Kim; Jae Lyun Lee; Hee Soon Cho; Sung Hwa Bae; Hun Mo Ryoo; Kyung Hee Lee; Myung Soo Hyun
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.